Press Releases:

Cardiovascular Disease: Could It Be a CoQ10 Deficiency?
Integrative Healthcare
Written by Dr. Rodger Murphree, D.C.   
Sunday, 04 March 2007 11:00 Read : 1803 times

heartmonitorDiscovered by researchers at the University of Wisconsin in 1957, Coenzyme Q10 (CoQ10), also known as ubiquinone, is a powerful antioxidant. Its name comes from the word ubiquitous, which means found everywhere. Indeed, CoQ10 is found in every cell in the body. This fat-soluble, vitamin-like enzyme is more abundant in some cells and organs than in others. It tends to congregate in the organs which need the most energy, especially the heart, brain and liver. The primary function of CoQ10 is to provide cellular energy. In each cell, there are organelles (small organ cells) known as mitochondria. Mitochondria are similar to a car’s cylinders. They allow a chain of chemical reactions to create a spark, which generates 95 percent of the body’s energy. CoQ10 is the spark that helps ignite adenosine triphosphate (ATP), the molecule that serves as the cell’s major energy source.

The importance of CoQ10 to maintain optimal health can’t be overstated. A growing body of research shows that CoQ10 may benefit a number of unwanted health conditions, including diabetes, periodontal disease, chronic fatigue, migraine headaches, skin cancers, diabetes, infertility, cardiovascular disease, immune dysfunction, asthma, muscular dystrophy, and Alzheimer’s, and Parkinson’s disease.

The body can’t manufacture CoQ10; instead, we must obtain CoQ10 from the foods we eat. Meat, dairy and certain vegetables, including spinach, and broccoli, contain the highest concentrations of CoQ10. However, obtaining adequate amounts of CoQ10 through diet alone poses a real challenge. It would take one pound of sardines, or two-and-a-half pounds of peanuts, to provide about 30mg of CoQ10. This is at the very minimum of the recommended daily allowance. In reality, the typical daily intake of CoQ10 from dietary sources is only about 3-5mg per day. This paltry amount isn’t anywhere near the level required to significantly raise blood and tissue levels.

And the fact that we tend to absorb and utilize less as we age increases the risk of developing a CoQ10 deficiency. Researchers estimate that as little as a 25 percent decline in bodily CoQ10 will initiate several disease states, including high blood pressure, heart disease, fatigue, cancer, and immune dysfunction.

What’s more, the biosynthesis of CoQ10 from the amino acid tyrosine is a complex, highly vulnerable seventeen-step process. It requires at least seven vitamins (vitamin B2, vitamin B3, vitamin B6, folic acid, vitamin B12, vitamin C, and B5) and several trace elements. Most American diets are deficient in at least one, if not all, of the cofactors for making CoQ10; seventy-one percent are deficient in vitamin B6 alone.

Dr. Karl Folkers, who has been honored with the Priestly Medal (the highest award bestowed by the American Chemical Society) for his work with CoQ10, believes that suboptimal nutrient intake in man is almost universal and these deficiencies prevent the biosynthesis of CoQ1O. He suggests that, since the average or "normal" levels of CoQ10 are really suboptimal, the very low levels observed in advanced disease states represent only the tip of a deficiency. Unless we are supplementing with CoQ10, we may be, in fact, suffering from a CoQ10 deficiency. Given the added stress posed in today’s society and the need for an ever increasing amount of antioxidants to counter this stress, could it be that many, if not all, of our chronic illnesses are due to suboptimal levels of CoQ10?

We know that a CoQ10 deficiency can cause muscle weakness, nerve damage (neuropathy), back pain, inflammation of tendons and ligaments, hypertension, heart disease, angina, accelerated aging, certain cancers, and various neurodegenerative diseases.

The cardiovascular system is especially vulnerable to CoQ10 deficiencies. The heart consumes huge amounts of CoQ10 initiated ATP. The muscles of the heart contract and relax some 100,000 times a day and pump blood through 60,000 miles of arteries and veins with each beat.

Dr. Folkers reports, "I believe it is quite possible that cardiovascular disease may be significantly caused by a deficiency of CoQ10. CoQ10 is known to be deficient in congestive heart failure (CHF), with the degree of deficiency in blood and cardiac tissue correlating with the severity of the CHF."

The results of using CoQ10 in treating cardiovascular related illnesses can be quite dramatic as the studies cited in the references on page 250 illustrate.

A group of class IV (terminal) CHF patients were supplemented with CoQ10 in addition to their prescription medications. Normally, class IV patients live only a matter of days. Seventy-one percent of those taking the CoQ10 survived one year and 62 percent survived two years!

Administering CoQ10 (50-150mg daily) for ninety days to 2,664 patients with CHF resulted in the following symptomatic and clinical improvements: cyanosis (bluish skin color), 78.1%; edema, 78.6%; pulmonary crackle, 77.8%; dyspnea (poor breathing), 52.7%; palpitations, 75.4%; sweating, 79.8%; arrhythmia (irregular heart beats), 63.4%; and vertigo, 73.1%.

CoQ10 significantly improves diastolic and systolic pressure in essential hypertension. Studies show that taking 100-225mg of CoQ10 a day reduces blood systolic blood pressure by an average of fifteen points and diastolic pressure by ten points. And more than half of patients receiving 225mg/day were able to terminate use of from one to three antihypertensive medications.

Mitral valve prolapse is a common condition associated with a heart murmur. It is often asymptomatic but can produce chest pain, arrhythmia, or leakage of the valve, leading to congestive heart disease. One study showed that, when children with mitral valve prolapse received CoQ10 (2 mg/kg a day) for eight weeks, heart function returned to normal in seven of the eight children; none of the placebo-treated patients improved. Relapse was common among those who stopped taking the medication within twelve to seventeen months, but rarely occurred in those who took CoQ10 for nineteen months or more.

In diabetes, which has several of the same characteristics as cardiovascular disease, CoQ10 has proven itself to be a valuable therapy for restoring normal blood sugar levels. CoQ10 has been shown to lower fasting blood glucose levels by 31 percent, while destructive ketone-bodies were reduced by a whopping 51 percent.

Even the common symptom of heart disease, chest pain, is no match for CQ10 therapy. Compared to placebo, CoQ10 was shown to reduce the frequency of angina or chest pain by 53 percent.

The benefits of CoQ10 in the treatment of cardiovascular disease are indisputable; CoQ10 should be the first line of therapy for anyone suffering from cardiovascular disease.

Yet, incredibly, the common drugs used as cardio-related drugs actually deplete CoQ10. Theses drugs include beta-blockers (Toprol, Tenormin, Coreg, Lopressor, Inderal, and others), vasodilators (hydralazine), thiazide diuretics (Aldactazide, Diuril, Dyazide, Moduretic, HydroDiuril, Micozide, and others), centrally-active hypertensives (Clonidine or Catapres, Aldoril, and Methyldopa) and, of course, lipid-lowering statins (Lipitor, Crestor, Zocor, Mevacor, Vytorin, and others).

Other drugs that deplete CoQ10 include anti-diabetic sulfonylureas drugs (Acetohexamides, Amaryl, Diabenese, Diabeta, Glucatrol, Micronase, Glyburide and Tolazamide), and tricyclic antidepressants (Elavil, Trazadone, Doxepin, Pamelor, and others).

Could it be that patients with cardiovascular-related illnesses actually accelerate their illness by taking these medications? Could the rise of statins and other popular cardio drugs, including beta-blockers, which deprive the heart of CoQ10, be the reason for the increase in hypertension, diabetes, heart disease and congestive heart failure (CHF)?

And, just as important, could these medications be causing or contributing to the chronic pain, fatigue, immune dysfunction, migraines, brain fog, hypertension, CHF, and or neuropathy symptoms of our patients? My experience suggests that they often do cause or contribute to the overall poor health of the patients I see, especially the complicated "medical misfits."

 

Dr. Murphree is a board certified nutritional specialist and chiropractic physician who has been in private practice since 1990. He is the founder and past clinic director for a large integrated medical practice located on the campus of Brookwood Hospital in Birmingham, Alabama. He is the author of five books for patients and doctors.

In 2002, Dr. Murphree sold his medical practice and now maintains a busy solo practice specializing in fibromyalgia, chronic fatigue syndrome, heart disease, mood disorders, and other chronic illnesses.

He can be reached toll free 1-888-884-9577 or at 1-205-879-2383; by email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it ; or visit www.TreatingandBeating.com.

References

1. Emile G. Bliznakov, M.D, and Gerald L. Hunt, The Miracle Nutrient Coenzyme Q10, Bantam Books, New York, NY. 1986.

2. Judy, W.V., Hall, J.H., Dugan, W., Toth, P.D, and Folkers, K. Coenzyme Q10 Reduction of Adrianmycin Cardiotoxicity. Biomedical and Clinical Aspects of Coenzyme Q10, Vol.4 pp.231-241, Elsevier Science Publ B.V., 1984.

3. Bliznakov EG. Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci USA. 1973 Feb; 70(2): 390-4.

4. Langjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 1994; 15:S265-S272.

5. Kamikawa et al., Effect of Coenzyme Q10 on Exercise Tolerance in Chronic Stable Angina Pectoris, Am. J. Cardiol: 56, 247, 1985.

6. Folkers K; Vadhanavikit S; Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A, 1985 Feb, 82:3,901-4.

7. Hattersley JG. Lowering cholesterol with Lovastatin. The wrong approach. A survey of usually overlooked literature. J Orthomolecular Med. 2004; 9(1): 54-7.

8. Ishiyama T, Morital Y, Toyama S et al. A clinical study of the effect of coenzyme Q10 on congestive heart failure. Jpn Heart J 1976; 17: 32.

9. Baggio E, Gandini R, Plancher AC. Italien multicenter study on the safety and efficacy of coenzyme Q10 as an adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15:s287-294.

10. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., Greco A.V., Littarru G.P. (1993) Evidence of Plasma CoQ10 - Lowering Effect by HMG-CoA Reductase Inhibitors: A double blind, placebo-controlled study. Clin. Pharmocol., J. 33, 3, 226-229.

11. What Your Doctor May Not Tell You About Hypertension. Mark Houston, M.D. pg 69-71. Warner Books New York, NY. 2003.

12.Simonsen, R., Two Successful Double-Blind Trials with Coenzyme Q10 on Muscular Dystrophies and Neurogenic Atrophies, Biochim. Biophys. Acta: 1271, 281, 1995.

13.Langsjoen et al., A Six-Year Clinical Study of Therapy of Cardiomyopathy with Coenzyme Q10, Int. J. Tissue React.: 12, 169, 1990

14.Oda, T. & Hamamoto, K., Effect of Coenzyme Q10 on the Stress-Induced Decrease of Cardiac Performance in Pediatric patients with Mitral Valve Prolapse, Jap. Circ. J.: 48, 1387, 1984.

15.Pelton R., LaValle J., Hawkins E., Krinsnsky D., Drug-Induced Nutrient Depletion Handbook, Natural Health Resources, 1999.

 


 
User Rating: / 1
PoorBest 
 

requestmagazinebutton


Advertisement

Advertisement

Advertisement

Recent Comments


Advertisement

 

TAC Publications

The American Chiropractor Magazine: Digital Issues | Past Issues | Buyer's Guide

 

More Information

TAC Editorial: About | Circulation | Contact

Sales: Advertising | Subscriptions | Media Kit